Blog
Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction
Key Points
- Interested in Arrowhead Pharmaceuticals, Inc.? Here are five stocks we like better.
- SHASTA-3 and SHASTA-4 topline data for plozasiran in severe hypertriglyceridemia remain on track
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data
Key Points
- Interested in Arvinas, Inc.? Here are five stocks we like better.
- Arvinas is narrowing its pipeline focus after the first PROTAC approval, concentrating internal investment on
Quanex Building Products Q2 Earnings Call Highlights
Key Points
- Interested in Quanex Building Products Corporation? Here are five stocks we like better.
- Quanex’s second-quarter revenue rose 2.2% to $462.4 million, but earnings fell sharply as
Navitas: NVIDIA’s AI Power Broker?
Key Points
- Interested in Navitas Semiconductor Corporation? Here are five stocks we like better.
- Navitas Semiconductor's integration into NVIDIA's MGX ecosystem, featuring 97.5% efficiency and
A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below
Key Points
- Interested in lululemon athletica inc.? Here are five stocks we like better.
- Lululemon's Q1 revenue of $2.47 billion beat a lowered consensus, but weak guidance and U.S. market
StealthGas Q1 Earnings Call Highlights
Key Points
- Interested in StealthGas, Inc.? Here are five stocks we like better.
- StealthGas posted higher Q1 revenue of $42.8 million, with adjusted net income of $15 million and adjusted EPS
NVIDIA's New Power Play: Why Fluence Is Surging
Key Points
- Interested in Fluence Energy, Inc.? Here are five stocks we like better.
- Fluence Energy's technology was integrated into a major industrial blueprint for next-generation NVIDIA-powered
Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge
Key Points
- Interested in Broadcom Inc.? Here are five stocks we like better.
- Broadcom shares picked up a huge amount of steam going into its earnings report, but that steam let off after
Saputo Q4 Earnings Call Highlights
Key Points
- Interested in Saputo Inc.? Here are five stocks we like better.
- Saputo’s profitability improved in Q4, with adjusted EBITDA up 5% to CAD 386 million and margin expanding to 9.2%
G-III Apparel Group Q1 Earnings Call Highlights
Key Points
- Interested in G-III Apparel Group, LTD.? Here are five stocks we like better.
- G-III beat first-quarter expectations with net sales of $536 million and a smaller-than-expected
ABM Industries Q2 Earnings Call Highlights
Key Points
- Interested in ABM Industries Incorporated? Here are five stocks we like better.
- ABM Industries posted strong Q2 fiscal 2026 results, with revenue up 8.4% to a record $2.3 billion
Five Below Down 12% Post Earnings—Is the Selloff Overdone?
Key Points
- Interested in Five Below, Inc.? Here are five stocks we like better.
- Five Below delivered revenue and earnings results that significantly exceeded analyst expectations.
- Investors
Arrow Financial Highlights Profit Gains, Adirondack Bank Deal at Annual Meeting
Key Points
- Interested in Arrow Financial Corporation? Here are five stocks we like better.
- Arrow Financial said 2025 was a transformational year, with stronger profitability, a return to
Tuniu Q1 Earnings Call Highlights
Key Points
- Interested in Tuniu Corporation? Here are five stocks we like better.
- Tuniu posted solid Q1 results, with net revenue up 13% year over year to CNY 132.6 million and its fifth
The Market Has Ollie’s Bargain Outlet Completely Wrong
Key Points
- Interested in Ollie's Bargain Outlet Holdings, Inc.? Here are five stocks we like better.
- Ollie's Bargain Outlet trades at roughly 17.5 times earnings, a discount to off-price peers
Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious
Key Points
- Interested in Macy's, Inc.? Here are five stocks we like better.
- Macy's delivered a broad-based earnings beat and raised its full-year outlook, providing further evidence that the
Buy the Dip? Broadcom's AI Moat Is Wider Than Ever
Key Points
- Interested in Broadcom Inc.? Here are five stocks we like better.
- Broadcom benefits from massive capital investments by major technology partners seeking to aggressively expand their
argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference
Key Points
- Interested in argenex SE? Here are five stocks we like better.
- argenx said its main priorities are revenue growth, profitability and execution as it expands the VYVGART franchise
Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies
Key Points
- Interested in Arcturus Therapeutics Holdings Inc.? Here are five stocks we like better.
- Arcturus Therapeutics is expanding beyond vaccines and is now emphasizing therapeutic mRNA
Amgen Touts MariTide, AI Gains and 2026 Growth Plans at Jefferies Conference
Key Points
- Interested in Amgen Inc.? Here are five stocks we like better.
- Amgen highlighted strong first-quarter performance, with revenue up 6% year over year and non-GAAP EPS up 5%
Alvotech Nears Inflection Point With 5 U.S. Biosimilars Targeted by Year-End
Key Points
- Interested in Alvotech? Here are five stocks we like better.
- Alvotech says it is at an “inflection point,” with management expecting five U.S. biosimilars on the market by year-end
Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial
Key Points
- Interested in Altimmune, Inc.? Here are five stocks we like better.
- Altimmune said it expects to begin enrolling patients in the second half of the year for its Phase 3 pemvidutide
Align Technology CFO: Global Growth, DSOs Offset North America Demand Pressure
Key Points
- Interested in Align Technology, Inc.? Here are five stocks we like better.
- Align Technology said international markets and North American DSOs are offsetting weakness in the U.S
Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment
Key Points
- Interested in Aldeyra Therapeutics, Inc.? Here are five stocks we like better.
- Aldeyra Therapeutics is awaiting near-term FDA feedback on its dry eye drug reproxalap after a third
Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near
Key Points
- Interested in Akebia Therapeutics, Inc.? Here are five stocks we like better.
- Vafseo uptake is improving, with Akebia saying the number of prescribing physicians rose 28% to about